Last Updated: 20 Sep 2024
Executive Summary
Shuttle Pharmaceuticals Inc. (SHPH) is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs to sensitize cancers to radiation therapy. Despite the company's efforts, it has yet to generate revenue and remains in the early stages of its development. The stock has experienced significant volatility in recent years, with a current price of $1.62.
Company Overview
Shuttle Pharmaceuticals was founded in 2014 and is headquartered in Rockville, Maryland. The company's lead drug candidate, SHP285, is a small molecule inhibitor of the SHP2 protein. SHP285 is currently in Phase 2 clinical trials for the treatment of advanced solid tumors.
Fundamental Analysis
Financial Performance: Shuttle Pharmaceuticals has not yet generated any revenue and continues to incur significant losses. In the latest quarter (ended June 30, 2024), the company reported an EBITDA loss of $57.4 million and a net loss of $3.44 per share.
Valuation: With no revenue or earnings, traditional valuation metrics such as P/E and P/B ratios are not applicable. The company's market capitalization of $36.97 million is based on its potential for future growth.
Risks: Shuttle Pharmaceuticals faces several risks, including the potential failure of its clinical trials, competition from other pharmaceutical companies, and the need for additional financing.
Technical Analysis
Trend: The stock price of SHPH has been in a downtrend since reaching a high of $5.44 in February 2022.
Support and Resistance Levels: The stock has found support at $1.28 and resistance at $2.54.
Moving Averages: The 50-day moving average is currently at $2.542, while the 200-day moving average is at $3.212.
Short Term Outlook
In the short term, the stock price of SHPH is likely to remain volatile. The company's upcoming clinical trial results will be a key catalyst for the stock. If the results are positive, the stock could rally. However, if the results are negative, the stock could decline further.
Long Term Outlook
The long-term outlook for Shuttle Pharmaceuticals depends on the success of its clinical trials and its ability to commercialize its products. If the company can successfully develop and market its drugs, it has the potential to become a major player in the cancer therapeutics market.
Analyst Recommendations
Currently, there are no analyst recommendations available for Shuttle Pharmaceuticals Inc.
